Anxious Depression & AZD2327

If you (or someone you know) have been diagnosed with major depression and have anxiety symptoms, you may be able to participate in an NIMH research study that seeks to decrease symptoms of depression and understand the causes of anxious depression. Anxiety symptoms may include tension, worry, apprehension, restlessness, or loss of appetite.

This study evaluates the effectiveness and safety of the study drug AZD2327, in the treatment of major depression and anxiety symptoms. This drug has a different mechanism of action from commonly used SSRIs (selective serotonin reuptake inhibitors) for anxiety and depression.   

This is a 12-week outpatient study including an inpatient stay of 4 days in Bethesda, MD. 

If you are 18-65 years of age and have been diagnosed with major depression and have anxiety symptoms, you may be eligible for this clinical trial. There is the chance of receiving placebo in this study.

After completion of the study, NIMH will provide short-term follow-up care, and then you will return to the care of your own provider.  In addition, all research participation is without cost and we will cover all transportation costs from anywhere in the United States.

Principal Investigator: 
National Institute of Mental Health
Contact: 
To find out if you qualify or for more information, please call 1-877-MIND-NIH (1-877-646-3644) or e-mail us at moodresearch@mail.nih.gov (TTY: 1-866-411-1010) Atendemos pacientes de habla hispana.
Location: 
Bethesda, MD
State: 
Maryland

Contact ADAA

8701 Georgia Ave., Suite #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.

 

Privacy Policy 
© ADAA, 2010-2014